MATINAS BIOPHARMA HOLDINGS, INC. Increase (Decrease) in Other Operating Liabilities
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Increase (Decrease) in Other Operating Liabilities of -$126.83 thousand for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2022-05-12
- MATINAS BIOPHARMA HOLDINGS, INC. increase (decrease) in other operating liabilities for the quarter ending 2022-03-31 was -$126.83K.
- MATINAS BIOPHARMA HOLDINGS, INC. increase (decrease) in other operating liabilities for the quarter ending 2021-12-31 was -$124.41K.
- MATINAS BIOPHARMA HOLDINGS, INC. increase (decrease) in other operating liabilities for the quarter ending 2021-09-30 was -$115.01K.
- MATINAS BIOPHARMA HOLDINGS, INC. increase (decrease) in other operating liabilities for the quarter ending 2021-06-30 was -$104.54K.
- MATINAS BIOPHARMA HOLDINGS, INC. increase (decrease) in other operating liabilities for fiscal 2021 was -$460.24K.
- MATINAS BIOPHARMA HOLDINGS, INC. increase (decrease) in other operating liabilities for fiscal 2020 was -$423.74K.
- MATINAS BIOPHARMA HOLDINGS, INC. increase (decrease) in other operating liabilities for fiscal 2019 was -$359.57K.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 12 month | Increase (Decrease) in Other Operating Liabilities 32 month |
|---|---|---|---|---|---|
| 2022-03-31 | -$126.83K 10-Q · filed 2022-05-12 | -$251.24K derived: sum of 2 quarters · filed 2022-05-12 | -$366.25K derived: sum of 3 quarters · filed 2022-05-12 | -$470.79K derived: sum of 4 quarters · filed 2022-05-12 | |
| 2021-12-31 | -$124.41K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-11 | -$239.42K derived: sum of 2 quarters · filed 2022-03-11 | -$343.96K derived: sum of 3 quarters · filed 2022-03-11 | -$460.24K 10-K/A · filed 2022-03-11 | |
| 2021-09-30 | -$115.01K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$219.55K derived: sum of 2 quarters · filed 2021-11-08 | -$335.83K 10-Q · filed 2021-11-08 | -$449.71K derived: sum of 4 quarters · filed 2022-05-12 | |
| 2021-06-30 | -$104.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$220.82K 10-Q · filed 2021-08-10 | -$334.70K derived: sum of 3 quarters · filed 2022-05-12 | -$443.80K derived: sum of 4 quarters · filed 2022-05-12 | |
| 2021-03-31 | -$116.28K 10-Q · filed 2022-05-12 | -$230.16K derived: sum of 2 quarters · filed 2022-05-12 | -$339.26K derived: sum of 3 quarters · filed 2022-05-12 | -$440.81K derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$113.88K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-11 | -$222.98K derived: sum of 2 quarters · filed 2022-03-11 | -$324.53K derived: sum of 3 quarters · filed 2022-03-11 | -$423.74K 10-K/A · filed 2022-03-11 | |
| 2020-09-30 | -$109.10K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$210.65K derived: sum of 2 quarters · filed 2021-11-08 | -$309.86K 10-Q · filed 2021-11-08 | -$407.02K derived: sum of 4 quarters · filed 2021-11-08 | |
| 2020-06-30 | -$101.55K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$200.76K 10-Q · filed 2021-08-10 | -$297.93K derived: sum of 3 quarters · filed 2021-08-10 | -$390.75K derived: sum of 4 quarters · filed 2021-08-10 | |
| 2020-03-31 | -$99.21K 10-Q · filed 2021-05-10 | -$196.38K derived: sum of 2 quarters · filed 2021-05-10 | -$289.20K derived: sum of 3 quarters · filed 2021-05-10 | -$375.00K derived: sum of 4 quarters · filed 2021-05-10 | |
| 2019-12-31 | -$97.17K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | -$189.99K derived: sum of 2 quarters · filed 2021-03-29 | -$275.78K derived: sum of 3 quarters · filed 2021-03-29 | -$359.57K 10-K · filed 2021-03-29 | |
| 2019-09-30 | -$92.82K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$178.62K derived: sum of 2 quarters · filed 2020-11-06 | -$262.40K 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | -$85.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$169.58K 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | -$83.79K 10-Q · filed 2020-05-11 | ||||
| 2014-09-30 | $207.57K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | $445.81K derived: sum of 2 quarters · filed 2014-11-14 | $370.09K 10-Q · filed 2014-11-14 | ||
| 2014-06-30 | $238.24K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $162.52K 10-Q · filed 2014-08-08 | |||
| 2014-03-31 | -$75.72K 10-Q · filed 2014-06-06 | $386.53K 10-Q · filed 2014-06-06 | |||
| 2013-09-30 | $198.10K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | $241.47K derived: sum of 2 quarters · filed 2014-11-14 | $241.47K 10-Q · filed 2014-11-14 | ||
| 2013-06-30 | $43.37K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $43.37K 10-Q · filed 2014-08-08 | |||
| 2013-03-31 | $0.00 10-Q · filed 2014-06-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |